Dr. Reddy’s inks COVID-19 licensing deal amid furore over IP waiver

India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca sues Dr Reddy's over breast cancer drug

14 February 2017 AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

Big Pharma

AIPPI weighs in on COVID waiver

17 May 2021 The International Association for the Protection of Intellectual Property has released a position paper on the proposed COVID-19 IP waiver, claiming that it will have a negative impact on the existing frameworks for promoting international cooperation and access to vaccines.

Big Pharma

President Xi supports COVID-19 waiver

1 June 2021 President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.

More on this story

Americas

AstraZeneca sues Dr Reddy's over breast cancer drug

14 February 2017 AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

Big Pharma

AIPPI weighs in on COVID waiver

Big Pharma

President Xi supports COVID-19 waiver

1 June 2021 President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.

More on this story

Americas

AstraZeneca sues Dr Reddy's over breast cancer drug

14 February 2017 AstraZeneca has filed a patent infringement claim against Dr Reddy's Laboratories over the drug Faslodex (fulvestrant) intramuscular injection, a treatment for breast cancer.

Big Pharma

AIPPI weighs in on COVID waiver

Big Pharma

President Xi supports COVID-19 waiver

1 June 2021 President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.